
PureTech Health gets US$11.4m to advance LYT-300
PureTech Health plc has been awarded up to $11.4 million from the US government to advance LYT-300 (oral allopregnanolone) for the treatment of...

Smarter, faster, cheaper: Veeva shows how
Achieving the highest possible speed in innovation to meet patients’ unmet needs. That was the palpable goal all the pharmaceutical and life sciences...

EG 427 expands Series A closing to €18m
EF 147, which got the additional €5m from undisclosed existing investors and new family office investors, is going to finance preclinical work upon...

More marine plastics than expected
Researchers led by Mikael Kaandorp from German FZ Jülich and colleagues from Utrecht University report that plastic pieces larger than 2.5 cm, which...

Dutch NLC has €20m in first close of new Health Impact Fund
According to NLC, there's a huge funding gap that prevents patents from becoming successful companies, with 95% of all healthtech inventions never...

Alnylam in US$2.8bn biobucks deal with Roche
The deal, which could fetch Alnylam Pharmaceuticals Inc up to US$2.8bn if all milestones are met and marketing approval is granted, clearly marks Big...

Lilly presents impressing results for Alzheimer's drug donanemab
Donanemab is the second antibody, after Eisai’s/Biogen’s accelarated approved lecanemab, that can slow the progression of dementia in early-stage...